A share price of Bicara Therapeutics Inc [BCAX] is currently trading at $20.96, up 2.49%. An important factor to consider is whether the stock is rising or falling in short-term value. The BCAX shares have gain 14.04% over the last week, with a monthly amount drifted -11.34%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bicara Therapeutics Inc [NASDAQ: BCAX] stock has seen the most recent analyst activity on November 05, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $48. On October 08, 2024, Stifel initiated with a Buy rating and assigned a price target of $47 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $35 on October 08, 2024. Cantor Fitzgerald initiated its recommendation with a Overweight.
Bicara Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $17.41 and $28.09. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Bicara Therapeutics Inc [NASDAQ: BCAX] shares were valued at $20.96 at the most recent close of the market. An investor can expect a potential return of 66.98% based on the average BCAX price forecast.
Analyzing the BCAX fundamentals
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.91 points at the first support level, and at 18.87 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.75, and for the 2nd resistance point, it is at 22.55.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Bicara Therapeutics Inc [NASDAQ:BCAX] is 36.01. On the other hand, the Quick Ratio is 36.01.
Transactions by insiders
Recent insider trading involved RA CAPITAL MANAGEMENT, L.P., Director, that happened on Sep 16 ’24 when 1.83 million shares were purchased. Possible Members of 10% Group, Flynn James E completed a deal on Sep 17 ’24 to buy 70000.0 shares.
